<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>64(2)</volume><submitter>French J</submitter><funding>Engage Therapeutics Inc.</funding><pubmed_abstract>&lt;h4>Objective&lt;/h4>Alprazolam administered via the Staccato® breath-actuated device is delivered into the deep lung for rapid systemic exposure and is a potential therapy for rapid epileptic seizure termination (REST). We conducted an inpatient study (ENGAGE-E-001 [NCT03478982]) in patients with stereotypic seizure episodes with prolonged or repetitive seizures to determine whether Staccato alprazolam rapidly terminates seizures in a small observed population after administration under direct supervision.&lt;h4&gt;Methods&lt;/h4>Adult patients with established diagnosis of focal and/or generalized epilepsy with a documented history of seizure episodes with a predictable pattern were enrolled. They were randomized 1:1:1 to double-blind treatment of a single seizure event with one dose of Staccato alp</pubmed_abstract><journal>Epilepsia</journal><pagination>374-385</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10107237</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination.</pubmed_title><pmcid>PMC10107237</pmcid><pubmed_authors>Detyniecki K</pubmed_authors><pubmed_authors>Dave H</pubmed_authors><pubmed_authors>Reich B</pubmed_authors><pubmed_authors>DiVentura B</pubmed_authors><pubmed_authors>O'Brien TJ</pubmed_authors><pubmed_authors>Sadek A</pubmed_authors><pubmed_authors>French J</pubmed_authors><pubmed_authors>Isojarvi J</pubmed_authors><pubmed_authors>Biton V</pubmed_authors><pubmed_authors>Liow K</pubmed_authors><pubmed_authors>Gong H</pubmed_authors><pubmed_authors>Gelfand MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination.</name><description>&lt;h4>Objective&lt;/h4>Alprazolam administered via the Staccato® breath-actuated device is delivered into the deep lung for rapid systemic exposure and is a potential therapy for rapid epileptic seizure termination (REST). We conducted an inpatient study (ENGAGE-E-001 [NCT03478982]) in patients with stereotypic seizure episodes with prolonged or repetitive seizures to determine whether Staccato alprazolam rapidly terminates seizures in a small observed population after administration under direct supervision.&lt;h4&gt;Methods&lt;/h4>Adult patients with established diagnosis of focal and/or generalized epilepsy with a documented history of seizure episodes with a predictable pattern were enrolled. They were randomized 1:1:1 to double-blind treatment of a single seizure event with one dose of Staccato alp</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-07-14T20:16:23.469Z</modification><creation>2025-04-04T07:11:19.004Z</creation></dates><accession>S-EPMC10107237</accession><cross_references><pubmed>36268811</pubmed><doi>10.1111/epi.17441</doi></cross_references></HashMap>